Data Supplement
- Supplemental Figure 1 -
Supplemental Figure 1 - Flow characteristics of all porcine livers during 360 min of normothermic perfusion, showing portal flow (A, D and G), arterial flow (B, E and H) and the cumulative bile production (C,F and I) livers exposed to atorvastatin, pitavastatin and rosuvastatin, respectively.
- Supplemental Figure 2 -
Supplemental Figure 2 - Plasma en bile pharmacokinetic profiles of all perfused livers (n=14).
- Supplemental Figure 3 -
Supplemental Figure 3 - Indocyanine green (ICG) clearance from plasma upon dosing ICG as an IV bolus (10 mg) to the perfusate 360 min after starting the liver perfusion and exposing livers to atorvastatin 1-4 (A), pitavastatin 2-5 (pitavastatin 1 NA: due to decrease in portal and arterial and bile flow) (B) and rosuvastatin (C).
- Supplemental Table 1 -
Table S1 - Perfusate composition.
- Supplemental Table 2 -
Supplemental Table 2 - Details of the LC/MS conditions used for the analysis of atorvastatin and atorvastatin metabolites, pitavastatin, rosuvastatin and rifampicin.
- Supplemental Table 3 -
Table S3 - The Multiple Reaction Monitoring Transition (MRM) of Compounds.
- Supplemental Table 4 -
Supplemental Table 4 - Multiple reaction monitoring (MRM) transitions of the various peptides and the corresponding internal standard (AQUA) used.
- Supplemental Table 5 -
Supplemental Table 5 - Absolute expression (fmol/mg tissue) of various uptake and efflux transporter proteins within the plasma membrane of porcine livers (n=5) compared to the protein expression in human liver (n=15).